1420367-28-7 (Lp-PLA2 -IN-1,Lp-PLA2-IN-1)

Lp-PLA2 -IN-1;

Lp-PLA2 -IN-1;Lp-PLA2-IN-1;GSK2814338;8-((3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-1-methyl-1,2,3,4-tetrahydro-6H-pyrimido[1,6-a]pyrimidin-6-one;Lp-PLA2 inhibitor;BCP23640;8-((3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-1-methyl-3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one;8-[[3,5-difluoro-4-[6-(trifluoromethyl)pyridin-3-yl]oxyphenyl]methoxy]-1-methyl-3,4-dihydro-2H-p;Lp-PLA2 -IN-1(GSK2814338)?;8-[[3,5-difluoro-4-[6-(trifluoromethyl)pyridin-3-yl]oxyphenyl]methoxy]-1-methyl-3,4-dihydro-2H-pyrimido[1,2-c]pyrimidin-6-one;GLXC-20570;VGC36728;EX-A1183;MS-28636;1420367-28-7;AKOS032945089;HY-19757;F85449;SCHEMBL14656135;DA-75105;CS-5918;GSK-2814338;Lp-PLA2 -IN-1;GSK 2814338;

QJIGPJZJKXZSNF-UHFFFAOYSA-N

1S/C21H17F5N4O3/c1-29-5-2-6-30-18(29)9-17(28-20(30)31)32-11-12-7-14(22)19(15(23)8-12)33-13-3-4-16(27-10-13)21(24,25)26/h3-4,7-10H,2,5-6,11H2,1H3

FC1C(=C(C([H])=C(C=1[H])C([H])([H])OC1C([H])=C2N(C(N=1)=O)C([H])([H])C([H])([H])C([H])([H])N2C([H])([H])[H])F)OC1=C([H])N=C(C(F)(F)F)C([H])=C1[H]